Wird geladen...
Targeted Radionuclide Therapy with A (177)Lu-labeled Anti-HER2 Nanobody
RIT has become an attractive strategy in cancer treatment, but still faces important drawbacks due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. Smaller radiolabeled antibody fragments and peptides feature highly specific target accumulation, resulting in low...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Ivyspring International Publisher
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4038753/ https://ncbi.nlm.nih.gov/pubmed/24883121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.8156 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|